Daewoong Hosts Global Aseptic Manufacturing Experts
Leading experts in global pharmaceutical manufacturing and quality technology gathered to directly inspect South Korea’s biopharmaceutical production sites. About 50 key officials from the Parenteral Drug Association (PDA) and domestic and overseas experts visited Daewoong Pharmaceutical’s new Nabot
Leading pharmaceutical manufacturing and quality technology experts from around the globe convened in South Korea to tour Daewoong Pharmaceutical's state-of-the-art Nabota plant and Bio Center in Hwaseong, Gyeonggi Province. Approximately 50 high-ranking officials from the Parenteral Drug Association (PDA) and experts from various countries visited the facilities on November 2, ahead of the 2026 PDA International Conference on Aseptic Processing of Biopharmaceuticals in Incheon.
The PDA Korea Chapter proposed the tour to showcase South Korea's growing bio industry and Nabota's global success.
Upon arriving at the new Nabota plant, the experts witnessed an automatic aseptic filling volume measurement system and automated packaging equipment, which significantly reduces manual intervention. The facility boasts enhanced quality data reliability by integrating the Warehouse Management System (WMS) and Laboratory Information Management System (LIMS). Daewoong Pharmaceutical plans to increase the plant's annual production capacity from 6 million vials to 12 million vials by adding two production lines in the future.
Next, the group visited Daewoong Bio's Bio Center, a fully integrated manufacturing facility that adheres to U.S. FDA cGMP and European Union GMP standards since its design. Completed in August 2024, the center features aseptic finished-product manufacturing capabilities for various products, including pre-filled syringes (PFS) and cartridges.
With an emphasis on EU GMP Annex 1 contamination control, the Bio Center utilizes Restricted Access Barrier System (RABS) technology and single-use bag systems to prevent contamination. In July, the facility obtained a CMO GMP conformity assessment from the Ministry of Food and Drug Safety for its PFS aseptic filling line.
Daewoong Pharmaceutical's Nabota Business Division head, Yoon Joon-su, expressed satisfaction with the visit, affirming the competitiveness of the new Nabota plant's aseptic manufacturing process. Similarly, Daewoong Bio's Bio Center head, Lee Ho-jin, highlighted the company's intention to expand its microorganism-based biopharmaceutical CMO business, leveraging the insights gained during the facility tour.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
